



**7 November 2024**

ASX Announcement

## **Island (ASX: ILA) Melbourne investor information session**

**MELBOURNE Australia, 7 November 2024:** Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to invite investors to an in-person information session on Friday, 15 November 2024, at 10.15am AEDT.

During this Melbourne briefing, Island CEO and Managing Director, Dr David Foster, will provide updates on the ISLA-101 Phase 2a/b PROTECT clinical trial, discuss the galidesivir due diligence program and cover other recent developments.

### **Event details**

Date: Friday 15 November  
Time: 10.15am AEDT arrival for a 10.30am AEDT start  
Location: Workspace 365 – Everest Room.  
Level 14, 330 Collins Street, Melbourne  
A light morning tea will be served.

To register your interest in attending in-person, please email Pip Thorn via [pip.thorn@irdepartment.com.au](mailto:pip.thorn@irdepartment.com.au) or phone +61 404 839 848.

The Island team looks forward to seeing all those investors who can attend this information session, or the Annual General Meeting in Sydney on Tuesday 19 November 2024. Details for the AGM are set out in the Notice of Meeting lodged with ASX on 18 October 2024.

**To subscribe to Island's monthly newsletter, *IslandWatch*, and other forms of email communications, please visit [this page](#) of our website.**

### **Approved for release to the ASX by:**

Dr Paul MacLeman  
Executive Chairman  
Island Pharmaceuticals Ltd  
[info@islandpharmaceuticals.com](mailto:info@islandpharmaceuticals.com)

Investors and media, for further information, please contact:

Jane Lowe  
IR Department  
Mobile: +61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)



## **About Island Pharmaceuticals**

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit [www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com) for more on Island.